BLOOMFIELD HILLS—Officials at TriMas Corp. (NASDAQ: TRS) announced the closing of the acquisition of Clinton Township-based Omega Plastics, a manufacturer of custom components and tooling for medical, as well as industrial applications, adding to TriMas’ Packaging group.
Omega uses its core injection molding capabilities, ISO Class 8 clean room and advanced in-house tool making capabilities, to provide its customers a faster product development cycle, from prototype development, testing and validation, to short and medium run production and assembly. Omega’s medical components are currently used in drug delivery, including consumable intravenous applications, as well as diagnostic testing and orthopedic applications.
As of Sept. 30, TriMas’ Packaging group’s last twelve months sales were approximately $534 million, representing approximately 64% of TriMas’ total sales. TriMas plans to expand Omega’s production capacity, as required in order to benefit its customers’ longer-term needs, while also leveraging Omega’s advanced tool making capabilities to add to TriMas Packaging’s speed-to-market advantage on innovation and new product designs. Omega is expected to generate approximately $18 million in revenue in fiscal year 2021.
“We welcome Omega to TriMas’ family of businesses and look forward to working with the Omega leadership team to unleash future growth opportunities,” said Thomas Amato, TriMas President & CEO. “I’d like to thank all the teams from Omega, TriMas and our respective advisors that supported the work to complete this transaction.”
The addition of Omega further expands TriMas Packaging’s Pharmaceutical & Nutraceutical product offering into supporting medical device contract development manufacturing customers.
TriMas is a global manufacturer of products for customers primarily in the consumer products, aerospace and industrial markets, with approximately 3,400 employees in 12 countries. More at www.trimascorp.com.